Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 7/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | DRD4 | P21917 | 4/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5585014 | 0.99 | MEN1 (0.41) | MEN1KMT2AHTR1ACCR1POLB | |
| SCHEMBL14571601 | 0.94 | HTR1A (0.41) | MEN1KMT2AHTR1ACCR1TSHR | |
| SCHEMBL5584936 | 0.93 | HTR1A (0.41) | MEN1KMT2AHTR1ACCR1POLB | |
| Hydrochloric Acid SCHEMBL6799510 | 0.92 | HTR1A (0.41) | MEN1KMT2AHTR1ACCR1POLB | |
| SCHEMBL14571577 | 0.91 | HTR1A (0.41) | MEN1KMT2AHTR1ACCR1POLB | |
| SCHEMBL8309550 | 0.91 | HTR1A (0.41) | MEN1KMT2AHTR1ACCR1POLB | |
| SCHEMBL14571583 | 0.91 | HTR1A (0.41) | MEN1KMT2AHTR1ACCR1POLB | |
| SCHEMBL14571540 | 0.91 | CCR1 (0.44) | MEN1KMT2AHTR1ACCR1POLB | |
| Hydrochloric Acid SCHEMBL5584294 | 0.90 | HTR1A (0.41) | MEN1KMT2AHTR1ACCR1POLB | |
| Hydrochloric Acid SCHEMBL5585058 | 0.90 | HTR1A (0.41) | MEN1KMT2AHTR1ACCR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | MEN1 2975/4885KMT2A 765/4885HTR1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.